## Policies to reduce drug expenditure without harming patients

Daniel Goldstein MD is a medical oncologist at Rabin Medical Center, a senior lecturer in Medical Oncology at Tel Aviv University and medical director of drug and technology policies in the community division of Clalit Health Services. He is responsible for developing policies that impact 4 million insurees. His area of research is in the global economics of cancer care, focusing on costeffectiveness, budget impact and affordability.



Dr Goldstein will discuss pharmacologic opportunities to reduce cancer drug expenditure without harming patient outcomes.

He will discuss the used of weight-based immunotherapy, used in multiple cancers, which can save 25% of resources.



He will also discuss the existence of class effects, which can also lead to significant cost savings (of up to 30%).

Please join us for this seminar at 4pm (Irish time) on the 23rd of May 2022:



